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Abstract
K562 cells, exposed for at least 24 h to 5 WM 3P-azido-3P-deoxythymidine (AZT), gave rise to an overall increase in the
number of cell surface transferrin binding receptors (18^20%). This effect was ascertained either with binding experiments by
using 125I-transferrin and with immunoprecipitation by using a specific monoclonal antibody against the transferrin receptor.
At higher AZT concentrations (20 and 40 WM), a further increase was found, that is, up to 23% by binding experiments and
up to 110% by immunoprecipitation. However, Scatchard analysis of the binding data indicated that although the number of
cell surface transferrin receptors increased, the affinity of transferrin for its receptor did not change (Ka = 4.0U108 M).
Surprisingly, immunoprecipitation of total receptor molecules showed that the synthesis of receptor was not enhanced by the
drug treatment. The effect of AZT on transferrin internalization and receptor recycling was also investigated. In this case,
data indicated that the increase in the number of receptors at the cell surface was probably due to a slowing down of
endocytosis rate rather than to an increased recycling rate of the receptor to cell surface. In fact, the time during which half
the saturated amount of transferrin had been endocytosed (t1=2) was 2.15 min for control cells and 3.41, 3.04, and 3.74 min
for 5, 20, and 40 WM AZT-treated cells, respectively. Conversely, recycling experiments did not show any significant
differences between control and treated cells. A likely mechanism through which AZT could interfere with the transferrin
receptor trafficking, together with the relevance of our findings, is extensively discussed. ß 1999 Elsevier Science B.V. All
rights reserved.
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2P,3P-dideoxyinosine; d4T, 2P^3P-didehydro-3P-deoxythymidine; FCS, fetal calf serum; HIV, human immunode¢ciency virus; Ka, apparent
association constant; mAb, monoclonal antibody; PBS (20 mM K-phosphate bu¡er, pH 7.2, containing 150 mM NaCl); NBT, nitro blue
tetrazolium chloride; NC, nitrocellulose; TBS (0.1 M Tris-HCl, pH 9.5, containing 1 mM MgCl2); Tf, transferrin; TfR, transferrin
receptor; TTBS (0.05 M Tris-HCl, pH 7.5, containing 0.05% (w/v) Tween-20 and 150 mM NaCl)
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1. Introduction
Zidovudine (3P-azido-3P-deoxythymidine or azido-
thymidine, AZT) has been the ¢rst antiretroviral
agent approved for clinical use, and it is still cur-
rently used in combination therapy of human immu-
node¢ciency virus (HIV) infection. AZT is active
against a broad range of retroviruses, including
HIV-2, human T-cell lymphotropic virus type 1,
and murine retroviruses [1]. It enters cells either by
passive di¡usion [2] or by an active process [3] and,
once inside, AZT undergoes a serial phosphorylation
processing by cellular kinases to its active form, that
is, AZT-5P-triphosphate (3P-azido-3P-deoxythymidine
triphosphate, AZTTP) [4]. AZTTP acts as a compet-
itor of endogenous thymidine-5P-triphosphate and
the azido group prevents the formation of normal
5P- to 3P-phosphodiester linkage causing termination
of the growing viral DNA chain. Although mamma-
lian DNA polymerase K is approximately 200-fold
less sensitive to AZTTP than HIV-1 reverse tran-
scriptase, other mammalian DNA polymerases,
such as DNA polymerases Q and L are more sensitive
to the triphosphate form of the drug [4^6]. This ¢nd-
ing may account for some of the toxicity found in a
subset of patients receiving long-term therapy with
AZT, who can develop myositis and other rare, but
potentially lethal, syndromes [7^9].
On the basis of increasing clinical reports and in
vitro studies, a strict correlation between AZT treat-
ment of HIV-positive patients and both the develop-
ment of anemia and iron overload have been evi-
denced during the last years [10^12]. Moreover,
Sommadossi and co-workers have reported that
AZT and its catabolite 3P-amino-3P-deoxythymidine
inhibit both hemoglobin synthesis and globin gene
transcription in butyric acid-induced K562 leukemia
cells [13,14] and in human hepatocytes [15]. Also, the
synthesis of heme in induced K562 cells was found to
be inhibited after prolonged exposure to high AZT
concentrations [14] and this might be an important
mechanism in the observed development of iron
overload.
Further observations [16] suggest that in AZT-
treated mice, an increase of non-heme iron amount
occurs both in the liver and in macrophages, the
increment being higher in hepatocytes, regardless of
the intensity and duration of the treatment. As the
main conclusion, the authors [16] hypothesize that
transferrin receptor (TfR) up-regulation synthesis
could be due to the inhibition of heme synthesis.
Lastly, it has been also demonstrated that intracellu-
lar iron levels a¡ect the amount of TfR mRNA by
modulating its stability in the cytoplasm ([17^19], for
review see [20]).
Physiologically, iron delivery to cells is mediated
by the iron carrier transferrin (Tf), which initially
binds to a speci¢c cell surface receptor, undergoes
endocytosis and, at the end of a short permanence
in the cell, it is ¢nally exocytosed [21]. It has been
found that in human erythroleukemia cells (K562)
the overall transit time is in the order of 16 min
[22]. Several studies have shown that many cells re-
ceive iron exclusively via the TfR, and Tf is indeed
necessary for in vitro cell growth [23,24]. Although
there is a close correlation between cell proliferation
and TfR expression in many cell types [25], there are
a number of non-proliferating cells, such as maturing
erythroid cells or placental trophoblast cells in which
the high iron requirement is re£ected by a high ex-
pression of TfR [26,27]. In these cellular systems, the
altered function of TfR can directly modulate iron
uptake. In fact, by changing either the rate of recep-
tor biosynthesis and/or degradation or the a⁄nity for
the ligand or the rate of endocytosis and/or exocyto-
sis with a shift in the location of the receptors within
the cell, so as to render them more or less available
to the ligand without altering the total number of
receptor molecules [28], the receptor function might
be modulated.
As a follow-up of the above-mentioned studies, the
aim of our work was to investigate, in an in vitro cell
culture system, the e¡ects of AZT on some aspects of
the basal iron metabolism. To this purpose, we have
exposed undi¡erentiated erythroleukemia cells
(K562) to various drug concentrations for 24 h and
the e¡ects of such treatments were evaluated in terms
of TfR binding capacity, receptor’s endocytosis/recy-
cling rate, and iron uptake.
2. Materials and methods
2.1. Materials
RPMI-1640 medium and fetal calf serum (FCS)
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were from Labtek-EUROBIO, (Les Ulis Cedex,
France). Human apoTf was purchased from Behring
(Marburg, Germany). Na125I (14.2 mCi/mg), 59FeCl3
(5 mCi/mg), and 14C-leucine (324 mCi/mmol) were
obtained from DuPont NEN (Brussels, Belgium). Io-
dogen (1,3,4,6-tetrachloro-3K,6K-diphenylglycouril)
was from Pierce (Rockford, USA). Monoclonal anti-
body (mAb) against TfR (clone VIP-1) was obtained
from BMA Biomedicals, Augst, Switzerland. AZT,
desferroxamine, alkaline phosphatase^anti rabbit
IgG conjugate, 5-bromo-4-chloro-3-indolyl phos-
phate p-toluidine salt (BCIP), nitro blue tetrazolium
chloride (NBT), Protein A-Sepharose 4B, bovine se-
rum albumin (BSA) were all purchased from Sigma
(St. Louis, USA). Acrylamide, bisacrylamide, molec-
ular weight standards, were from Bio-Rad (Rich-
mond, USA). Nitrocellulose (NC) (OPTITRAN
BA-S 85-Schleicher and Schuell, Dassel, Germany)
was used as immobilizing matrix. Liquid scintillation
cocktail (PICO-FLUOR 15) was purchased from
Packard Instrument, Meriden, CT, USA. All other
chemicals were reagent grade.
2.2. Cells
Human erythroleukemia cells (K562), kindly sup-
plied by Dr. L. Di Renzo (Laboratory of Experimen-
tal and Pathlogic Medicine, University of Rome ‘La
Sapienza’), were grown in suspension in RPMI-1640
bicarbonate medium (pH 7.2) and 10% (v/v) heat-
inactivated FCS containing 2 mM glutamine, supple-
mented with 0.1 mg/ml of both penicillin and strep-
tomycin, at 37‡C and 5% CO2 in an air-humidi¢ed
atmosphere. Cells, at the density of 1.5U105 cells/ml,
were grown in the absence or in the presence of AZT
at three di¡erent concentrations (5, 20, 40 WM) for 24
h in routine experiments. All experiments were per-
formed on cells in the logarithmic phase of growth.
Cell growth did not show any appreciable change at
all the experimental conditions we used. Cell viability
was checked at the end of the treatments by Trypan
blue exclusion method and was always found higher
than 95%.
2.3. Radiolabeling
125I-Tf radiolabeling was performed following the
standard protocol based on the use of Iodogen. The
speci¢c activity was approximately 65 kCi/mol of
protein. 59Fe-Tf radiolabeling was carried out by
the addition of an appropriate amount of 59Fe (as
59FeCl3) to the apo-form of Tf [29]. The speci¢c ac-
tivity ranged from 3.5 to 4.5 kCi/mol of protein in
di¡erent preparations.
2.4. Binding of transferrin to cell surface TfRr
For binding assays, 2U106 cells in 200 Wl fresh
RPMI-1640 iron-free medium containing 1% (w/v)
BSA, were incubated at 4‡C for 90 min with 100 Wl
of 125I-Tf at increasing concentrations from 1 to 50
nM. Binding was terminated by addition of 2 ml of
ice-cold RPMI/BSA medium; the cells were then pel-
leted by centrifugation at 400Ug at 4‡C for 5 min.
After two washes in the same medium, the cell pellet
was resuspended in 2.5 ml of liquid scintillation
cocktail and the incorporated radioactivity was de-
termined in a Packard TRI-CARB L-counter. The
non-speci¢c binding was assessed in a parallel sample
by addition of 100-fold excess of unlabeled ligand
5 min before the addition of the radiolabeled ligand.
2.5. Immunoblotting of total TfRs
K562 cells (1U107/well), cultured with or without
AZT for 24 h, were washed twice with PBS (20 mM
K-phosphate bu¡er, pH 7.2, containing 150 mM
NaCl) and treated with lysis bu¡er (10 mM Tris-
HCl, pH 7.5, containing 2% (v/v) Nonidet P-40, 0.1
mM phenylmethylsulfonyl £uoride and 1 mM dithio-
threitol) at 4‡C for 20 min. The solubilized cells were
centrifuged for 30 min at 3500Ug and 4‡C and the
resulting supernatant was resolved by SDS-PAGE on
a 7.5% gel according to Laemmli [30]. The proteins
were blotted onto NC as described by Towbin et al.
[31] with slight modi¢cations. The membrane was
blocked with 5% (w/v) fat-free milk in TTBS (0.05
M Tris-HCl, pH 7.5, containing 0.05% (w/v) Tween-
20 and 150 mM NaCl). After blocking, the NC mem-
branes were incubated for 1 h with mAb anti-human
TfR diluted 1:10 000 in TTBS. Then, after four
washing steps, incubated for 2 h with biotin^anti-
rabbit IgG conjugate, diluted 1:10 000 and ¢nally,
after further four washing steps, incubated for 1 h
with alkaline phosphatase^Extravidine conjugate di-
luted 1:300 000. Immunoblots were developed by in-
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cubation with 10 ml substrate solution made with 9.9
ml TBS (0.1 M Tris-HCl, pH 9.5, containing 1 mM
MgCl2), 45 Wl BCIP (13 mg/ml in dimethylform-
amide) and 55 Wl NBT (20 mg/ml in 70% (v/v) di-
methylformamide).
2.6. SDS-PAGE resolution of cell surface TfRs
Cells were treated as above, but before being lysed,
they were incubated at 4‡C for 2 h with monoclonal
antibody anti-human TfR (20 Wg) and, after four
PBS washing steps, lysis treatment followed. Subse-
quently, samples were incubated with Protein A-Se-
pharose 4B at 4‡C for 1 h. Then, beads were washed
six times with PBS bu¡er containing 50 mM EDTA
and 0.65 M NaCl. Following elution with Laemmli’s
sample bu¡er [30], the TfRs were resolved by SDS-
PAGE on 7.5% gel and the bands visualized by silver
staining [32].
2.7. Immunoprecipitation of total metabolically
labeled TfRs
Metabolic labeling was carried out by incubating
K562 cells with 5 WCi 14C-leucine in the presence or
in the absence of AZT for 24 h. Then, labeled K562
cells (5U106/well) were washed twice with PBS and
treated with lysis bu¡er as above. The solubilized
cells were incubated at 4‡C for 2 h with mAb anti-
human TfR (20 Wg) and then, after four PBS washing
steps, incubation with Protein A-Sepharose 4B at
4‡C for 1 h, followed. The beads were washed six
times with PBS bu¡er containing 50 mM EDTA
and 0.65 M NaCl and the radioactivity was eval-
uated in a Packard TRI-CARB L-counter.
2.8. Cell surface localization of the metabolically
labeled TfRs
K562 cells (1U107/well), metabolically labeled
with 14C-leucine as reported above, were washed
twice with PBS and incubated in RPMI-1640 at
4‡C for 2 h with mAb anti-human TfR. Cells were
then washed four times with PBS to remove the ex-
cess of unbound antibody, and solubilized with lysis
bu¡er at 4‡C for 20 min. The solubilized cells were
centrifuged for 30 min at 4‡C and 3500Ug and the
pellet was discarded. The supernatant was treated
with 100 Wl of Protein A-Sepharose 4B, for 60 min
at 4‡C and pelleted. The beads were washed four
times with PBS, dissolved in 2.5 ml scintillation cock-
tail and radioactivity measured.
2.9. Endocytosis of TfR
Internalization of radiolabeled Tf-TfR complex
was determined by incubating K562 cells, treated as
reported for binding assay, with 125I-Tf at 37‡C.
Then, stripping, of any ligand bound to the cell sur-
face was achieved by an acid/neutral treatment [33].
Brie£y, cells were harvested, washed and resuspended
in warm RPMI/BSA medium as for binding assay.
Labeled ligand (0.5 WM) was added and 125I-Tf in-
ternalization was stopped at various times by remov-
ing aliquots (1U106 cells) from the incubation mix-
ture and diluting them into 20 vols. of ice-cold acid
bu¡er (100 mM NaCl, 50 mM citric acid, pH 5.0,
0.2% (w/v) BSA, 50 WM desferroxamine). After 10^
30 min, cells were pelleted and resuspended in PBS
(pH 7.4) containing 50 WM desferroxamine and 0.2%
(w/v) BSA, then incubated for a further 15 min. The
surface Tf stripped cells were pelleted and the radio-
activity evaluated.
2.10. TfR recycling assay
To measure recycling rates, 1U107 cell/ml pre-
pared as for endocytosis experiments, were incubated
with 125I-Tf (0.5 WM) for 30 min at 37‡C in order to
label the internal pool of TfR. After 1 h, unlabeled
Tf (4 mg/ml, ¢nal concentration) was also added to
the incubation mixture. At various times samples of
1U106 cells were stripped of surface-bound Tf by the
acid/neutral treatment [33], and 125I-Tf still associ-
ated with the cells was measured.
2.11. Iron uptake
For uptake experiments, untreated or AZT-treated
K562 cells (1U107 cells/ml) were incubated at 37‡C
with 385 pmol of 59Fe-Tf for increasing time periods.
Aliquots of 200 Wl in duplicate were withdrawn at
di¡erent time intervals and mixed with 1 ml ice-
cold RPMI-1640 iron-free medium. The mixture
was layered over 300 Wl of dibutyl phthalate in 1.5-
ml disposable polypropylene tubes and spun for
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10 min at 400Ug and 4‡C. Intracellular 125I-Tf was
determined by incubating the cells at low pH in
bu¡er containing diethylenetriaminepentaacetic acid
and washed twice in order to remove all radioactivity
from the surface of cells. To correct for non-speci¢c
uptake, controls containing 100-fold excess of unla-
beled Tf were run in parallel.
3. Results
3.1. Binding assays
The number of TfRs on the K562 cell surface was
determined by performing ligand binding assays at
4‡C. Cell suspensions were exposed to di¡erent ex-
perimental conditions as indicated in Table 1.
Scatchard analysis of the speci¢c binding isotherms
yielded the average values for both the maximum
binding sites per cell (Bmax) and the apparent associ-
ation constant (Ka), as reported in Table 1. Cells
treated with 5, 20, or 40 WM AZT exhibited an in-
crease of the number of TfR on the cell surface with
respect to control cells, ranging between 18 and 23%,
while no change of Ka value (4.0U108 M) was ob-
served.
3.2. Total content of TfR
To investigate if the increased number of total
TfRs in AZT-treated cells was due to an increase
of the receptor biosynthesis or if the observed up-
regulation was the result of a redistribution of recep-
tors, we ¢rst determined the total amount (i.e. intra-
cellular plus surface) of TfR in control and AZT-
treated K562 cells. In this case, as shown in Fig. 1,
immunoblotting of both control and AZT-treated
cell lysates, incubated with mAb anti-human TfR
exhibited a single band with almost the same inten-
sity (Mr 90 kDa). Moreover, when 14C-leucine meta-
bolically labeled cells were immunoprecipitated, no
signi¢cantly quantitative di¡erence in the biosynthe-
sis of the receptors was evidenced (Table 2).
3.3. Cell surface amount of TfR
Both the SDS-PAGE analysis of cell surface TfR
(Fig. 2) and immunoprecipitation of the metabol-
ically labeled cell surface TfR (Table 3) showed a
global increase of the receptor amount in the treated
Table 1
The average apparent association constant (Ka) and maximum
binding sites/cell (Bmax) calculated from the 4‡C isotherm of
binding of transferrin to K562
125I-Tf 24 h
Bmax v (%) KaU1038 (M31)
Control 234 900 þ 23 300 ^ 4.0 þ 0.8
5 WM AZT 277 236 þ 20 912 18 3.9 þ 0.8
20 WM AZT 276 268 þ 20 806 18 4.2 þ 1.0
40 WM AZT 290 000 þ 22 032 23 4.0 þ 1.2
Cells were treated as described in Section 2. Brie£y, 2U106 cells
in 200 Wl fresh RPMI-1640 iron-free medium containing 1% (w/
v) BSA, were incubated at 4‡C for 90 min with 100 Wl of 125I-
Tf at increasing concentrations from 1 to 50 nM. Binding was
terminated by addition of 2 ml of ice-cold RPMI/BSA medium.
Cells were then washed in the same medium, the cell pellet was
resuspended in 2.5 ml of liquid scintillation cocktail and the in-
corporated radioactivity was measured in a Packard TRI-
CARB L-counter. The non-speci¢c binding was assessed in a
parallel sample by addition of 100-fold excess of unlabeled lig-
and 5 min before the addition of the radiolabeled ligand. Val-
ues are means þ S.D. of four independent experiments from
four independent cell growths. v (%), percent increase of cell
surface binding TfR number with respect to control cells.
Fig. 1. Immunoblotting of total TfRs. K562 cells (107/well)
were cultured for 24 h without (lane A) or with AZT (lane B,
5 WM; lane C, 20 WM; lane D, 40 WM). Then, samples were
prepared as reported in the speci¢c section in Section 2. St,
molecular weight standards.
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cell samples which fairly paralleled the increasing
AZT concentrations.
3.4. Endocytosis and recycling of TfR
Endocytosis of iron saturated transferrin into the
cells gave a typical saturation curve which was well
¢tted by a single exponential equation (Table 4)
[34,35]. A signi¢cant slowing down of the endocy-
totic process was induced especially in cells treated
with 40 WM AZT. In fact, the value of the rate con-
stant for the internalization of ligand^receptor com-
plexes (kL in Table 4) related to the treated cells
showed a decrease of 42% after 24 h incubation,
t1=2 being 2.15 and 3.74 min, for control and AZT-
treated cells, respectively (Table 4). Furthermore, the
steady-state saturating amount of Tf (Lo values in
Table 4) was instead rather una¡ected at the various
AZT concentrations assayed.
Concerning recycling experiments, they could be
performed by monitoring the decrease in radioactiv-
ity inside the cells. When data were ¢tted as addition
of two separate exponentials : the fast step, corre-
sponding to TfR directly recycled outside, accounted
for about 65^75% of total labeled Tf, while the slow
step, corresponding to the receptor fraction recycled
through the Golgi apparatus accounted for about
20^25%. The remaining 5^10% represented the
amount that was retained inside the cell, both in
control and AZT-treated cells. No di¡erences were
found between control and AZT-treated cells (Table
5).
3.5. Iron uptake
Intracellular accumulation of iron in control or
AZT-treated cells showed a very similar pattern at
all AZT concentrations tested. In particular, the de-
livery rate of the radiolabeled iron associated with
cells during the ¢rst 20 min did not change signi¢-
cantly in the presence or in the absence of AZT (Ta-
ble 6), in spite of the higher number of binding re-
ceptors on the surface of treated cells (Tables 1 and
3).
3.6. Other experimental conditions
Using the same AZT concentrations, we also
tested shorter incubation times (i.e. 3, 6, 12, 18 h)
but no e¡ects at all were found; by contrast, at lon-
ger times (i.e. 48, 72 h) all the results we obtained
were quite similar to those reported after 24 h incu-
bation, then, no more signi¢cant information could
be added (data not shown). Experiments were also
performed at lower AZT concentrations (1 and
3 WM), but no e¡ects were observed at the di¡erent
incubation times (3, 6, 12, 18, 24, 48, 72 h) (data not
shown).
Fig. 2. SDS-PAGE of cell surface TfRs. K562 cells (107/well)
were cultured for 24 h without (lane A) or with AZT (lane B, 5
WM; lane C, 20 WM; lane D, 40 WM). Then, samples were pre-
pared as reported in the speci¢c section in Section 2. St, molec-
ular weight standards.
Table 2
Immunoprecipitation of total metabolically labeled receptors
Total 14C-TfR immunoprecipitated 24 h (cpmU106 cells31)
Control 2058 þ 198
5 WM AZT 2241 þ 119
20 WM AZT 2180 þ 136
40 WM AZT 2103 þ 200
Metabolic labeling was carried out by incubating K562 cells
with 5 WCi 14C-leucine in the presence or in the absence of
AZT for 24 h. Labeled K562 cells (5U106/well) were washed
twice with PBS and lysed with lysis bu¡er at 4‡C for 20 min.
The solubilized cells were centrifuged for 30 min at 3500Ug
and 4‡C, the resulting supernatant was incubated at 4‡C for 2 h
with mAb anti-human TfR (20 Wg) and then, with Protein A-
Sepharose 4B at 4‡C for 1 h. The beads were washed six times
with the same bu¡er containing 50 mM EDTA and 0.65 M
NaCl and radioactivity evaluated in a Packard TRI-CARB L-
counter. Values are means þ S.D. of four independent experi-
ments from four independent cell growths.
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4. Discussion
The internalization pathway of TfR in K562 cells
has investigated in depth to de¢ne both functional
parameters of endocytosis and the regulation of the
receptor membrane tra⁄c itself [36^39]. Moreover, it
is known that the cellular population of TfR is dis-
tributed between the intracellular compartment and
the cell surface, being 14^25% the total receptor pool
embedded in the plasma membrane of K562 cells at
any time [33,36]. However, as a consequence, any
alteration in the cellular distribution of receptors
causes either an increase or a decrease in the number
of cell surface receptors.
In our experimental system, considering a molar
ratio of 1:2 = TfR:Tf [40], the number of binding
receptors increased from about 117 000 receptors in
control cells up to about 145 000 (+23%) in 40 WM
AZT-treated cells, with no change of the Ka values
(Table 1). However, it should be pointed out that
this number of receptors (binding receptors) repre-
sents just a fraction of the total cell surface receptors.
In our conditions, the increment seemed not to be
due to an increase of TfR synthesis. In fact, either
immunoblotting experiments (Fig. 1) or immunopre-
cipitation (Table 2) showed no signi¢cant di¡erences
in TfR synthesis of untreated and AZT-treated cells.
In addition, a further con¢rmation of this observa-
tion was obtained by determination of the TfR
mRNA (data not shown), which again showed no
signi¢cant di¡erence between controls and AZT-
treated cells under the same experimental conditions.
As a partial support to binding experiments, both
SDS-PAGE analysis (Fig. 2), and immunoprecipita-
tion of cell surface TfR (Table 3) showed an increase
of TfRs directly correlated to AZT concentration.
Interestingly, taking into account data reported in
Tables 2 and 3, in agreement with other studies
[33,36], the receptor amount located on the control
cell surface was only about 17% with respect to the
Table 4
Kinetic parameters for the internalization of transferrin in K562
125I-Tf 24 h
L0U1035 (molecules/cell) kL (min31) t1=2 (min)
Control 8.48 þ 1.06 0.321 þ 0.075 2.15
5 WM AZT 8.78 þ 1.59 0.203 þ 0.022 3.41
20 WM AZT 8.86 þ 0.83 0.228 þ 0.043 3.04
40 WM AZT 9.69 þ 0.15 0.185 þ 0.001 3.74
Experimental results for Tf^TfR complex internalization were ¢tted by using the equation: L  L013exp3kLt, where L is the
amount of Tf endocytosed, L0 is the saturating amount of Tf, kL is the rate constant for the internalization of Tf^TfR complex, and
t is time. t1=2 is the time during which half the saturated amount of Tf had been endocytosed. Data given are means þ S.D. of four in-
dependent experiments from four independent cell growths. t1=2 has been calculated from the mean value for kL.
Table 3
Immunoprecipitation of cell surface metabolically labeled receptors
Cell surface 14C-TfR immunoprecipitated 24 h (cpmU106 cells31) TfRa v (%)
Control 347 þ 89 136 080 ^
5 WM AZT 475 þ 75 186 280 37
20 WM AZT 602 þ 86 236 080 73
40 WM AZT 730 þ 108 286 280 110
Metabolic labeling was carried out by incubating K562 cells with 5 WCi 14C-leucine in the presence or in the absence of AZT for 24
h. Labeled K562 cells (5U106/well) were incubated at 4‡C for 2 h with mAb anti-human TfR (20 Wg) and then, with Protein A-Se-
pharose 4B at 4‡C for 1 h. The beads were washed six times with the same bu¡er containing 50 mM EDTA and 0.65 M NaCl and
the radioactivity associated was evaluated. Values are means þ S.D. of four independent experiments from four independent cell
growths. v (%), percent increase of total cell surface TfR number with respect to control cells.
aAverage TfR number derived from leucine content in human TfR [50] and our experimental conditions.
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total TfR (347 vs. 2058 cpm). Furthermore, concern-
ing the number of cell surface TfRs, by comparing
Tables 1 and 3 one could infer that: (1) in control
cells, binding TfRs represented about 86% of total
cell surface TfRs (117450 vs. 136080); and (2) AZT
treatment of K562 cells led to an overall increase of
surface TfRs, both of binding and non-binding type.
Nevertheless it seems interesting to notice that the
fractional increase was due mainly to non-binding
type TfRs, leading to the hypothesis that AZT a¡ects
the TfR redistribution at membrane level.
The ¢nding of an increased fractional number of
binding receptors induced us to try to clarify the
di¡erent steps of iron cycle in AZT-treated K562
cells. When 125I-Tf was monitored for its entry into
the cell, a marked decrease of the rate constant for
the internalization of transferrin^receptor complex
(kL), with a consequent increase of the t1=2, was evi-
denced in AZT-treated cells (Table 4). This result
suggested that endocytosis was signi¢cantly slowed
down by the presence of the drug.
Moreover, our experimental data on the TfR re-
cycling pattern agreed with the existence of di¡erent
pathways through two separate cellular compart-
ments, as already reported [41]. In fact, the time-de-
pendent decrease we found could not be described by
a single exponential decay, but by the sum of two
exponential decays; furthermore, there was always a
little amount of 125I-Tf which did not leave the cells,
i.e. the radioactivity never approached zero with
time. The best ¢t was obtained when the sum of
two exponential decays in time and a time-independ-
ent constant was used to describe the experimental
data of recycling. The fast and slow rate constant of
recycling steps were essentially the same either in
control and in treated cells irrespective of the AZT
concentration, thus demonstrating the substantial
lack of any e¡ect of AZT on the global recycling
pathway (Table 5).
The data on the recycling process, taken together,
seem to indicate that no signi¢cant modi¢cation of
this process occurred in the presence of AZT. Then,
as a consequence of the balance between a slower
endocytosis and a normal recycling of TfR, one
could expect, as indeed we found, a greater number
of receptors on the cell surface of treated cells.
It was also evaluated if these changes in the endo-
cytosis rate could be correlated to an altered iron
uptake. In our experimental conditions, the amount
Table 6
Total cellular uptake of59Fe-transferrin
59Fe-Tf 24 h
(iron atom/cell)aU1034 ku (min31)
Control 5.48 þ 0.60 0.51 þ 0.05
5 WM AZT 4.73 þ 0.35 0.44 þ 0.03
20 WM AZT 5.37 þ 0.15 0.50 þ 0.01
40 WM AZT 3.87 þ 0.22 0.36 þ 0.02
Untreated or AZT-treated K562 cells (1U107 cells) were incu-
bated with 385 pmol of 59Fe-Tf for increasing time periods. Ex-
perimental results were ¢tted by a straight line where ku is the
slope. Values are means þ S.D. of four independent experiments
from four independent cell growths.
aAt 20 min.
Table 5
Kinetic parameters characterizing the recycling of transferrin in K562 cells
125I-Tf 24 h
Lf Ls Lr kf (min31) ks (min31) t1=2f (min) t1=2s (min)
Control 0.660 0.280 0.060 0.36 þ 0.05 0.025 þ 0.007 1.93 27.7
5 WM AZT 0.644 0.255 0.101 0.38 þ 0.07 0.030 þ 0.008 1.87 23.1
20 WM AZT 0.668 0.285 0.047 0.40 þ 0.06 0.028 þ 0.009 1.73 24.7
40 WM AZT 0.737 0.211 0.052 0.38 þ 0.01 0.031 þ 0.001 1.82 22.3
Recycling was measured and characterized by 125I radioactivity remaining associated with the cells. Recycling was studied after load-
ing cells at 37‡C and then depleting the surface of cells at 4‡C by an acid/neutral washing. The best ¢t was obtained with the follow-
ing equation: L  Lf exp3kf t  Lsexp3kst  Lr, where L is the ratio of amount of ligand remained associated with the cells at
time t to the amount of Tf associated with the cells at t = 0 min; Lf , Ls, Lr are di¡erent protein ‘pools’ for which the condition of
Lf +Ls+Lr = 1 should be ful¢lled; kf and ks are time constants for the fast and the slow recycling processes. t1=2f and t1=2s are the times
during which half of the appropriate Tf ‘pool’ (i.e. Lf and Ls) become empty. Results from four independent experiments were used
for curve ¢tting. Lf , Ls, and Lr were varied in 0.01 steps. t1=2f and t1=2s have been calculated from the mean value for kf and ks, re-
spectively. Data given are means þ S.D. of four independent experiments from four independent cell growths.
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of the total iron both internalized and on the cell
surface, in AZT-treated cells was found to be not
signi¢cantly di¡erent with respect to control cells
(Table 6). The apparently contradictory lack of in-
creased iron uptake in spite of the higher number of
TfR on the cell surface of treated cells, could be
partly explained matching the higher number of
TfR with the slowing down of endocytosis rate, re-
sulting in the internalization of an unaltered amount
of iron per time unit.
On the other hand, it is noteworthy that the ¢rst
remarkable e¡ects we observed were after 24 h,
which is almost the normal duplication time of our
cells [42], and at 5 WM AZT, which is the usual
plasma concentration of this drug during clinical
treatment [43].
Enlightenment on the mechanism, by which AZT
reduces the rate of TfR endocytosis, could be derived
from comparison between the e¡ects of many drugs
and compounds that are reported in literature to act
at di¡erent stages of the iron cycle [28,41,44]. By
considering our data, since until now no e¡ects of
AZT have been reported on microtubules depolym-
erization, a mechanism of action of AZT similar to
that of nocodazole-like drugs could be excluded [41]
as well as the in£uence of AZT on protein phospho-
rylation because the e¡ects we found occurred after
hours and not minutes [28,45]. By contrast, as de-
scribed elsewhere [46,47], the up-regulation of TfR
due to a decrease in membrane £uidity and change
in membrane phospholipid composition, cannot be
excluded.
Furthermore, it has been reported that 3P-azido-3P-
deoxythymidine monophosphate, the primary intra-
cellular metabolite of AZT, is a potent inhibitor of
lipid and protein glycosylation in K562 cells [48],
nearly abolishing ganglioside synthesis and incorpo-
ration of sialic acid and galactose into proteins [49].
Although in this case a direct e¡ect of AZT on the
synthesis and transport to the outside membrane of
TfR has to be excluded, the dramatic overall e¡ect of
AZT on the glycosylation of both proteins and lipids
most probably compromise the function of mem-
brane receptors [49]. It has also been pointed out
by the same authors that ddC, ddI, and d4T, other
nucleotide analogous used in the treatment of HIV
infection, do not form phosphorylated metabolites
and do not a¡ect glycosylation pattern [49]. In line
with these ¢ndings, in our experimental conditions,
we found no e¡ects of these drugs on TfR distribu-
tion and function (data not shown).
The data we obtained, compared with those from
other authors, led us to hypothesize that the AZT-
induced altered glycosylation in K562 cells might
also a¡ect TfR exposure and functionality, in£uenc-
ing the early steps of endosome formation and slow-
ing down the endocytosis rate. Further work is cur-
rently in progress in our laboratory to study the
e¡ect of AZT on the expression of speci¢c glycosyl-
transferases and glycosidases.
Our ¢nding that AZT did not signi¢cantly a¡ect
the iron uptake via TfR, con¢rmed the idea that the
action of this drug on the iron metabolism is prob-
ably a multi-factorial process, then, the iron amount
taken up via TfR, by itself, does not probably ac-
count for the iron overload.
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